
OpenCRISPR-1: The First AI-Designed Gene Editor
The first AI-designed CRISPR gene editor validated in human cells. Open source, high specificity, and free to license for research and commercial use.
Published findings for biological design are buried in papers and supplements. Ambryon extracts them, links them and cites them.
Indexed: 351 parts, 447 papers
Promoters, capsids, nucleases, base editors, reporters and regulatory elements.
Published constructs with annotated maps.
Papers with their key findings extracted and linked to the parts they concern.
Registered trials by vector, route of administration and indication.
Most of what is known about a part sits in PDFs, supplements and figure legends. Each finding here is extracted, linked to the part it concerns and cited.
Ambryon is a curated knowledge library for biological design. It links parts, designs, literature and clinical trials, so each design choice can be traced to its published evidence.
Scientists and engineers who design vectors, gene editors and other genetic constructs, in academic labs and in industry.
Parts such as promoters, AAV serotypes, nucleases and base editors; published designs drawn as construct maps; the papers that describe them with their key findings; and clinical trials.
Yes. Every index and every record page is public.
Not to search or read. A free account opens the full sequence of every part and design.
Each record is curated from published literature and public trial registries, and links to its sources so you can check them yourself.
Yes. Individual records can be used in commercial work. Copying the Library in bulk, redistributing it and training models on it are not permitted. The Terms of service give the details.
A free account opens the full sequence of every part and design.

The first AI-designed CRISPR gene editor validated in human cells. Open source, high specificity, and free to license for research and commercial use.

How dual AAV systems deliver large genes for Stargardt, Usher 1B, and muscular dystrophy. Manufacturing realities, clinical progress, and competitive outlook.

Economic analysis of rare disease gene therapy development: from clinical trial advantages and pricing dynamics to manufacturing costs and business viability.